Patents by Inventor Tooru Ooya
Tooru Ooya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190358331Abstract: A DDS carrier enabling sustained release of a drug and a production method therefor. Wherein, the drug is retained by a PEG-carboxy group-containing polymer graft. Among polymers, a carboxy group-containing polysaccharide can be suitably used. The PEG-carboxy group-containing polymer graft is a compound prepared by grafting PEG into the carboxy group-containing polysaccharide. When the carboxy group-containing polysaccharide is used, it can be produced by utilizing a condensation reaction of an aminated PEG and a carboxy group-containing polysaccharide in coexistence with a triazine-based condensing agent. Alternatively, the PEG-carboxy group-containing polysaccharide graft can be produced by utilizing a condensation reaction of PEG and a carboxy group-containing polysaccharide in coexistence with an acid.Type: ApplicationFiled: August 9, 2019Publication date: November 28, 2019Inventors: Ying-shu Quan, Tooru Ooya, Rongrong Jiang, Fumio Kamiyama
-
Publication number: 20180193465Abstract: A DDS carrier enabling sustained release of a drug and a production method therefor. Wherein, the drug is retained by a PEG-carboxy group-containing polymer graft. Among polymers, a carboxy group-containing polysaccharide can be suitably used. The PEG-carboxy group-containing polymer graft is a compound prepared by grafting PEG into the carboxy group-containing polysaccharide. When the carboxy group-containing polysaccharide is used, it can be produced by utilizing a condensation reaction of an aminated PEG and a carboxy group-containing polysaccharide in coexistence with a triazine-based condensing agent. Alternatively, the PEG-carboxy group-containing polysaccharide graft can be produced by utilizing a condensation reaction of PEG and a carboxy group-containing polysaccharide in coexistence with an acid.Type: ApplicationFiled: July 13, 2016Publication date: July 12, 2018Inventors: Ying-shu Quan, Tooru Ooya, Rongrong Jiang, Fumio Kamiyama
-
Patent number: 7829337Abstract: A cell-sheet releasing agent of the present invention contains an aminated polyrotaxane. The polyrotaxane constituting the skeleton of the cell-releasing agent of the present invention has a structure in which cavities of a plurality of cyclic molecules are threaded onto a linear molecule and both terminals of the linear molecule have a bulky cap bonded thereto so that the cyclic molecules are not dethreaded from the linear molecule. Furthermore, the aminated polyrotaxane contained in the cell-releasing agent of the present invention is a compound in which at least some of hydroxy groups in the cyclodextrin structure contained in the polyrotaxane are each substituted with a substituent having an amino group. According to this cell-sheet releasing agent, cultured cells anchored to the surface of a container can be released without damaging the cells and without controlling the temperature.Type: GrantFiled: September 9, 2005Date of Patent: November 9, 2010Assignees: Japan Science And Technology Agency, Japan Tissue Engineering Co., Ltd., Japan Advanced Institute of Science And TechnologyInventors: Wanpen Tachaboonyakiat, Masakazu Kato, Tooru Ooya, Nobuhiko Yui
-
Publication number: 20100161021Abstract: This invention relates to a myocardial pad used in cardioversion, pacing, or the like and to a myocardial lead and a therapeutic apparatus for cardiac disease comprising the same. The myocardial pad of this invention is bondable to epicardia and has conductivity, biocompatibility, and biodegradability. Using this pad, the myocardial lead can be immobilized onto the atrium without suture. Thus, bleeding from the atrium, which is a lethal complication, caused by lead removal can be prevented.Type: ApplicationFiled: June 7, 2007Publication date: June 24, 2010Applicants: National University Corporation Kanazawa University, Japan Advanced Institute Of Science And TechnologyInventors: Kenji Iino, Go Watanabe, Nobuhiko Yui, Tooru Ooya, Ryoji Kawabata
-
Publication number: 20080038821Abstract: A cell-sheet releasing agent of the present invention contains an aminated polyrotaxane. The polyrotaxane constituting the skeleton of the cell-releasing agent of the present invention has a structure in which cavities of a plurality of cyclic molecules are threaded onto a linear molecule and both terminals of the linear molecule have a bulky cap bonded thereto so that the cyclic molecules are not dethreaded from the linear molecule. Furthermore, the aminated polyrotaxane contained in the cell-releasing agent of the present invention is a compound in which at least some of hydroxy groups in the cyclodextrin structure contained in the polyrotaxane are each substituted with a substituent having an amino group. According to this cell-sheet releasing agent, cultured cells anchored to the surface of a container can be released without damaging the cells and without controlling the temperature.Type: ApplicationFiled: September 9, 2005Publication date: February 14, 2008Applicants: JAPAN SCIENCE AND TECHNOLOGY AGENCY, JAPAN TISSUE ENGINEERING CO., LTD.Inventors: Wanpen Tachaboonyakiat, Masakazu Kato, Tooru Ooya, Nobuhiko Yui
-
Patent number: 7041310Abstract: This invention provides to a novel pharmaceutical preparation for the treatment of gynecological diseases. The pharmaceutical preparation according to the invention comprises a therapeutic drug for the intrauterine, intravaginal or intrapelvic administration, or for the administration into the ovarian endometrioma, and a biodegradable polymer comprising a chemically modified hyaluronic acid or a salt thereof prepared by O-acylating, alkoxylating or crosslinking a complex of hyaluronic acid or a salt thereof and a cationic compound in a nonaqueous solvent. The preparation of the invention is preferably administered intrauterine, intravaginal, intrapelvic, and intratumor cavity.Type: GrantFiled: March 28, 2002Date of Patent: May 9, 2006Assignees: Chisso CorporationInventors: Nobuhiko Yui, Kouichi Murakami, Tooru Ooya, Ikuo Sato
-
Publication number: 20050003013Abstract: A drug is provided comprising of a degradable gel with a saturated moisture content not exceeding 98 wt. % and a functional material, and which permits control of the rate of release of the functional material and performs controlled-release of the functional material over a prolonged period of time, and wherein the gel itself decomposes and dissipates upon completion of release of the functional material.Type: ApplicationFiled: April 22, 2004Publication date: January 6, 2005Inventors: Nobuhiko Yui, Koichi Murakami, Tooru Ooya, Ikuo Sato, Tuyoshi Nakama, Ryouji Kawabata
-
Publication number: 20040265389Abstract: To provide degradable gel hardly degradable and having enough strength, and a method for producing the same.Type: ApplicationFiled: April 22, 2004Publication date: December 30, 2004Inventors: Nobuhiko Yui, Tooru Ooya, Tuyoshi Nakama, Ikuo Sato, Ryouji Kawabata
-
Publication number: 20040162275Abstract: A multivalently interactive molecular assembly having a plurality of functional groups or ligands, in which a ratio between Rh and Rg expressed as Rh/Rg is 1.0 or less. Here, Rh is a hydrodynamic radius calculated from dynamic light scattering (DLS) assay performed in aqueous solution; and Rg is a radius of gyration determined based on the Zimm plot generated using data obtained by static light scattering (SLS) assay.Type: ApplicationFiled: October 7, 2003Publication date: August 19, 2004Applicant: Nobuhiko YuiInventors: Nobuhiko Yui, Atsushi Maruyama, Tooru Ooya
-
Patent number: 6673919Abstract: This invention relates to a chemically modified hyaluronic acid and salts thereof, which are obtained by O-acylating, alkoxylating or crosslinking a complex consisting of hyaluronic acid or a salt thereof and a cationic compound in a nonaqueous solvent, and a process for the production thereof. The nonaqueous solvent used in the invention is preferably one or more solvents selected from the group consisting of chloroform, toluene, methylene chloride and heptane.Type: GrantFiled: March 28, 2002Date of Patent: January 6, 2004Assignees: Chisso CororationInventors: Nobuhiko Yui, Tooru Ooya, Ikuo Sato
-
Publication number: 20030171573Abstract: A multivalently interactive molecular assembly having a plurality of functional groups or ligands, in which a ratio between Rh and Rg expressed as Rh/Rg is 1.0 or less. Here, Rh is a hydrodynamic radius calculated from dynamic light scattering (DLS) assay performed in aqueous solution; and Rg is a radius of gyration determined based on the Zimm plot generated using data obtained by static light scattering (SLS) assay.Type: ApplicationFiled: August 29, 2002Publication date: September 11, 2003Inventors: Nobuhiko Yui, Atsushi Maruyama, Tooru Ooya
-
Publication number: 20030124168Abstract: Base materials for tissue regeneration which enable the tissue regeneration, have mechanical properties needed in the tissue regeneration and can disappear via degradation in vivo after the completion of the tissue regeneration; and implantable materials with the use of the same. The above-described base materials for tissue regeneration comprise polyrotaxane, wherein biocompatible groups having bulky substituents have been introduced via hydrolyzable bond into both ends of a linear molecule penetrating plural cyclic molecules, or a polyrotaxane hydrogel having a network structure formed by crosslinking the cyclic molecules to each other, the biocompatible groups to each other, or the cyclic molecules to the biocompatible groups in each polyrotaxane molecule.Type: ApplicationFiled: December 30, 2002Publication date: July 3, 2003Applicant: JAPAN TISSUE ENGINEERING CO., LTD.Inventors: Nobuhiko Yui, Tooru Ooya, Masakazu Kato, Takeyuki Yamamoto
-
Publication number: 20020150605Abstract: This invention provides to a novel pharmaceutical preparation for the treatment of gynecological diseases. The pharmaceutical preparation according to the invention comprises a therapeutic drug for the intrauterine, intravaginal or intrapelvic administration, or for the administration into the ovarian endometrioma, and a biodegradable polymer comprising a chemically modified hyaluronic acid or a salt thereof prepared by O-acylating, alkoxylating or crosslinking a complex of hyaluronic acid or a salt thereof and a cationic compound in a nonaqueous solvent. The preparation of the invention is preferably administered intrauterine, intravaginal, intrapelvic, and intratumor cavity.Type: ApplicationFiled: March 28, 2002Publication date: October 17, 2002Inventors: Nobuhiko Yui, Kouichi Murakami, Tooru Ooya, Ikuo Sato
-
Publication number: 20020143171Abstract: This invention relates to a chemically modified hyaluronic acid and salts thereof, which are obtained by O-acylating, alkoxylating or crosslinking a complex consisting of hyaluronic acid or a salt thereof and a cationic compound in a nonaqueous solvent, and a process for the production thereof. The nonaqueous solvent used in the invention is preferably one or more solvents selected from the group consisting of chloroform, toluene, methylene chloride and heptane.Type: ApplicationFiled: March 28, 2002Publication date: October 3, 2002Applicant: CHISSO CORPORATIONInventors: Nobuhiko Yui, Tooru Ooya, Ikuo Sato